Profile
Philip J.
Barr was the founder of Arriva Pharmaceuticals, Inc. founded in 1997, where he held the title of Chief Scientific Officer from 1997 to 2011.
Dr. Barr is also the founder of BayMedica, Inc. Dr. Barr's current job is as a Principal at The University of California, San Francisco.
Dr. Barr's former job was as a Director-Molecular Biology at Chiron Corp.
Philip J. Barr active positions
| Companies | Position | Start |
|---|---|---|
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
BayMedica, Inc.
BayMedica, Inc. BiotechnologyHealth Technology Operates biosynthetic platform for the production of cannabinoids | Founder | - |
Former positions of Philip J. Barr
| Companies | Position | End |
|---|---|---|
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory therapies for treating respiratory diseases | Founder | 18/01/2011 |
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Corporate Officer/Principal | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory therapies for treating respiratory diseases | Health Technology |
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BayMedica, Inc.
BayMedica, Inc. BiotechnologyHealth Technology Operates biosynthetic platform for the production of cannabinoids | Health Technology |
- Stock Market
- Insiders
- Philip J. Barr
















